Last reviewed · How we verify
Celecoxib(drug)
Celecoxib(drug) is a Selective COX-2 inhibitor (coxib) Small molecule drug developed by Chinese University of Hong Kong. It is currently in Phase 3 development for Rheumatoid arthritis, Osteoarthritis, Acute pain. Also known as: Celebrex.
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Celecoxib(drug) |
|---|---|
| Also known as | Celebrex |
| Sponsor | Chinese University of Hong Kong |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
As a selective COX-2 inhibitor, celecoxib preferentially blocks COX-2 while sparing COX-1, which is responsible for protective gastrointestinal and renal functions. This selectivity was designed to provide anti-inflammatory and analgesic effects with reduced gastrointestinal toxicity compared to non-selective NSAIDs. By inhibiting COX-2-derived prostaglandins, it reduces inflammation, pain, and fever.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Familial adenomatous polyposis (FAP)
Common side effects
- Dyspepsia
- Abdominal pain
- Diarrhea
- Headache
- Hypertension
- Cardiovascular events (myocardial infarction, stroke)
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (PHASE2)
- A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis (PHASE1)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas (PHASE1)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Metformin Safety and Efficacy in Osteoarthritis. (PHASE3)
- TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celecoxib(drug) CI brief — competitive landscape report
- Celecoxib(drug) updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI
Frequently asked questions about Celecoxib(drug)
What is Celecoxib(drug)?
How does Celecoxib(drug) work?
What is Celecoxib(drug) used for?
Who makes Celecoxib(drug)?
Is Celecoxib(drug) also known as anything else?
What drug class is Celecoxib(drug) in?
What development phase is Celecoxib(drug) in?
What are the side effects of Celecoxib(drug)?
What does Celecoxib(drug) target?
Related
- Drug class: All Selective COX-2 inhibitor (coxib) drugs
- Target: All drugs targeting COX-2 (Cyclooxygenase-2)
- Manufacturer: Chinese University of Hong Kong — full pipeline
- Therapeutic area: All drugs in Rheumatology / Pain Management
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Osteoarthritis
- Indication: Drugs for Acute pain
- Also known as: Celebrex
- Compare: Celecoxib(drug) vs similar drugs
- Pricing: Celecoxib(drug) cost, discount & access